LEADING ARTICLE

Causation of human ulcerative colitis: A lead from an animal model that mirrors human disease

William E W Roediger

Department of Surgery and Gastroenterology, University of Adelaide at The Queen Elizabeth Hospital, Adelaide, Australia

Abstract

Most models of experimental colitis do not replicate human ulcerative colitis and do not help in defining the causation of human ulcerative colitis. Inducing pantothenic acid deficiency in pigs produces an ideal model in terms of extent, histology, and chronicity of human ulcerative colitis. Comparing metabolic changes in human ulcerative colitis with metabolic changes in experimental colitis in pigs provided a guide for the search of initiating factors of human ulcerative colitis. Observations showed that bacterial nitric oxide with bacterial hydrogen sulphide reproduced the metabolic changes of human ulcerative colitis. Decreasing colon-produced nitric oxide and hydrogen sulphide by bacteria through diet and medication resulted in pronounced therapeutic improvement, both clinically and histologically, of human ulcerative colitis.

Introduction

The causation of human ulcerative colitis is unknown. Observations from an ideal model of experimental colitis in pigs provided a lead toward causative agents in human ulcerative colitis.

A large number of models of colitis have been described in experimental animals. Most of these models are produced by rectal instillation of acetic acid, ethanol, trinitrobenzene sulfonic acid, formalin, and hydrogen peroxide or by oral ingestion of sulphated polysaccharides. Histologically, these animal models of experimental colitis do not resemble human ulcerative colitis nor do they reflect the chronicity of the human disease. On these grounds, animal models are not identical to human disease.

An ideal model of experimental colitis

A remark by August Krogh was that, for many research problems, there is an animal on which it can be most conveniently studied (the August Krogh principle). Such an animal for ulcerative colitis was the pig, in which a model of experimental colitis could be induced by pantothenic acid (vitamin B₅) deficiency. Pantothenic acid deficiency was induced by a diet free of pantothenic acid. Colitis developed 2–3 weeks after the pantothenic acid deficient diet was started. The colitis progressed from mild to moderate to severe and began at the rectum and progressed proximally. Maintaining a pantothenic acid-free diet eventually led to the death of the pigs. This model, histologically, very closely resembles human ulcerative colitis (Figs 1–3). It is an ‘ideal’ model in that, in distribution along the colon and chronicity, it reflects human ulcerative colitis. Unfortunately, the model was reported in 1943, in a journal that has ceased publication and for which no electronic version is available. Consequently, the model has received only two citations since 1943, and these are prior to 1976. One purpose of this report is to republish the histological findings (Figs 1–5) and also to indicate that the model may be a lead to the causative factors of human ulcerative colitis.

Pantothenic acid (Vit B₅) deficiency

What is the role of pantothenic acid in tissues, and what does pantothenic acid deficiency result in? Worth noting is that pantothenic acid deficiency cannot be established in humans but is readily established in various animals.

Pantothenic acid is required in all tissues for the synthesis of coenzyme A, a compound that is essential in the tissues of the body for chemical energy production, that is, adenosine triphosphate (ATP). One of the tissues is the lining epithelial cells, also referred to as colonocytes, of the colon mucosa. A decrease in energy production by human colonocytes has been found in ulcerative colitis.

Before proceeding, it is important to outline the substrate needs of colonocytes. Colonocytes in man and animals do not oxidize or produce energy from glucose but preferentially oxidize n-butyrate, which provides 70% of the energy for healthy colonocytes. n-Butyrate is produced by the bacterial fermentation of dietary fiber in the colonic lumen. The oxidation of n-butyrate is referred to as beta-oxidation, a metabolic pathway that requires four times more coenzyme A than the pathway of glucose oxidation. Tissues highly reliant on coenzyme A would...
therefore be most prone to cell damage in pantothenic acid deficiency.

**Beta oxidation in colonocytes of human ulcerative colitis**

The inhibition of beta oxidation of n-butyrate can be experimentally induced either acutely in rats over 4 days or more chronically in pigs over several days. Colitis due to the inhibition of beta oxidation, either acutely or chronically, produces histological features not unlike human ulcerative colitis.

Inhibition of beta oxidation in colonocytes of acute and chronic human ulcerative colitis was reported in 1980 and was subsequently confirmed in humans, in vivo, by several researchers. Consequently, a prolonged search was carried out for the agents causing inhibition of beta oxidation in humans. Two agents, nitric oxide and sulphide, acting together, were found to inhibit beta oxidation and lower coenzyme A levels in healthy human colonocytes. Nitric oxide in colonocytes would react with the thiol group of coenzyme A. The resultant product...
is a “nitrosothiol” that, in human ulcerative colitis, was found to be elevated.\textsuperscript{18}

The two agents, nitric oxide and hydrogen sulphide, are bacterial metabolites. Production of these metabolites, particularly sulphide, depends on a high intake of meat\textsuperscript{19} or sulfur amino acids. Reducing sulfur amino acid intake in the diet\textsuperscript{20} or reducing sulphide production from colonic bacteria with 5-aminosalicylic acid,\textsuperscript{21,22} the active therapeutic moiety of salazopyrin,\textsuperscript{23} leads to amelioration of attacks of active ulcerative colitis.\textsuperscript{24}

Parallelism between experimental and human ulcerative colitis

A close parallel between human ulcerative colitis and the ideal model of experimental ulcerative colitis can be drawn (Fig. 5). The steps outlined in the human and animal diseases are congruous and have been biochemically validated as indicated by the references shown in Figure 5. Metabolic changes in the colonic mucosa of human disease and animal colitis are correlated.

Conclusions

An ideal model of experimental colitis in pigs has long been disregarded and “lost,” yet it provides a guide to the causation of human ulcerative colitis. Removing the causative factors of human ulcerative colitis, that is, bacterially produced nitric oxide and hydrogen sulphide, provides a therapeutic gain. Both experimental colitis and human ulcerative colitis are reversible diseases by removing the causative factors. What remains to be done is to identify which bacteria, and their metabolic activity in the microbiome, produce the causative factors leading to human ulcerative colitis.

References

1. Kim H-S, Berstad A. Experimental colitis in animal models. \textit{Scand. J. Gastroenterol}. 1992; 27: 529–37.
2. Morson BC. Pathology of ulcerative colitis. In: Kirchner JB, Shorter RG (eds). \textit{Inflammatory Bowel Disease}. Philadelphia: Lea and Febiger, 1975; 169–81.
3. Krogh A. The progress of physiology. \textit{Am. J. Physiol}. 1929; 90: 243–51.
4. Krebs HA. The August Krogh Principle “For many problems there is an animal on which it can be most conveniently studied”. \textit{J. Exp. Zool}. 1975; 194: 221–6.
5. Wintrobe MM, Follis RH, Alcayaga R, Paulson M, Humphreys S. Pantothenic acid deficiency in swine. \textit{Bull. Johns Hopkins Hosp}. 1943; 73: 313–40.
6. Roediger B. \textit{Causative Factors of Ulcerative Colitis and Crohn’s Disease. An Exploratory Guide}. Adelaide: Wakefield Press, 2016; 1–104.
7. Leonardi R, Zhang YM, Rock CO, Jackowski S. Coenzyme A: back in action. \textit{Prog. Lipid Res}. 2005; 44: 125–53.
8. Roediger W. The colonic epithelium in ulcerative colitis—an energy deficiency disease? \textit{Lancet}. 1980; 316: 712–5.
9. Gibson PR. Ulcerative colitis: an epithelial disease? \textit{Bailliere’s Clin. Gastroenterol}. 1997; 11: 17–33.
10. Roediger W. Utilization of nutrients by epithelial cells of the colon. \textit{Gastroenterology}. 1982; 83: 424–9.
11. Roediger W. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. \textit{Gut}. 1980; 21: 793–8.
12. Nelson DL, Cox MM, eds. \textit{Lehninger Principles of Biochemistry}. New York: Freeman and Company, 2008; 652–5.
13. Roediger W, Nance S. Metabolic induction of experimental ulcerative colitis by inhibition of fatty acid oxidation. \textit{Br. J. Exp. Path}. 1986; 67: 773–82.
14. Cheldelin VH, Nygaard AP, Hale OM, King TE. Pantothenic acid involvement in fatty acid oxidation. \textit{J. Am. Chem. Soc}. 1951; 73: 5004–5.
15. Den Hond E, Hiele M, Evenpoel P, Peeters M, Ghosu Y, Rutgeerts P. In vivo butyrate metabolism and colonic permeability in extensive ulcerative colitis. \textit{Gastroenterology}. 1998; 115: 584–90.
16. Kato K, Ishii Y, Mizuno G \textit{et al}. Usefulness of rectally administering (I-13C)-butyrate for breath test in patients with active and quiescent ulcerative colitis. \textit{Scand. J. Gastroenterol}. 2007; 42: 207–14.
17 Roediger WEW, Babidge WJ. Nitric oxide effect of colonocyte metabolism: co-action of sulphides and peroxide. Mol. Cell. Biochem. 2000; 206: 159–67.
18 Roediger WEW, Cummins A, Cowled A. Tissue nitrosothiol levels in acute ulcerative colitis—a step in disease induction? Nitric Oxide. 2008; 195: S46.
19 Magee EA, Richardson CJ, Hughes R, Cummings JH. Contribution of dietary protein to sulphide production in the large intestine: an in vitro controlled feeding study in humans. Am. J. Clin. Nutr. 2000; 72: 1488–94.
20 Roediger WEW. Decreased sulphur amino acid intake in ulcerative colitis. Lancet. 1998; 351: 1555.
21 Roediger WEW, Duncan A. 5-ASA decreases colonic sulphide formation: implications for ulcerative colitis. Med. Sci. Res. 1996; 24: 27–9.
22 Pitcher MCL, Beatty ER, Cummings JH. Contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis. Gut. 2000; 46: 64–72.
23 Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977; 310: 892–5.
24 Jowett SL, Seal CJ, Pearce MS et al. Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. Gut. 2004; 53: 1479–84.
25 Nelson RA. Interstitial transport, coenzyme A, and colitis in pantothenic acid deficiency. Am. J. Clin. Nutr. 1968; 21: 495–501.
26 Ellestad-Sayed JJ, Nelson RA, Adson MA, Palmer WM, Soule EH. Pantothenic acid, coenzyme A and human chronic ulcerative colitis and granulomatous colitis. Am. J. Clin. Nutr. 1976; 29: 1333–8.